Virtual tumor predicts response to liver cancer immunotherapy

Article excerpt

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks growth signals on which the tumor depends. The work, supported in part by the National Institutes of Health, was published online July 14 in the Proceedings of the National Academy of Sciences.